Onco3R Therapeutics

Executive Summary

Onco3R Therapeutics is a private, clinical-stage Belgian biotech company focused on developing next-generation precision medicines for oncology and immunology. Founded in 2020 and headquartered in Leuven, the company targets novel pathways including SIK3, FGFR3, SMARCA2, and P53, aiming to address unmet needs in cancers with high genetic heterogeneity. By leveraging a deep understanding of tumor biology and immune evasion mechanisms, Onco3R seeks to create targeted therapies that improve patient outcomes. While specific pipeline details are limited, the company's emphasis on diverse oncology targets suggests a strategic approach to tackling multiple cancer types, including those driven by FGFR alterations, SMARCA2 mutations, or p53 dysfunction. As a private entity, Onco3R's progress is less transparent, but its clinical-stage status indicates that at least one program has advanced to human trials.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 data readout for lead SIK3 inhibitor in solid tumors40% success
• Q1 2027IND filing for FGFR3-targeted antibody in bladder cancer60% success
• Q3 2026Preclinical proof-of-concept for novel SMARCA2 degrader in NSCLC50% success